Overuse of long-acting β₂-agonist/inhaled corticosteroids in patients with chronic obstructive pulmonary disease: time to rethink prescribing patterns

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD) [Internet]. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: updated 2023 2023. [cited 2023 Feb 1]. Available from: https://goldcopd.org/2023-gold-report-2/
   Google Scholar
• Celli B, Fabbri L, Criner G, et al. Definition and nomenclature of chronic obstructive pulmonary disease: time for its revision. Am J Respir Crit Care Med. 2022;206(11):1317–1325. doi: 10.1164/rccm.202204-0671PP
   PubMed Web of Science ®Google Scholar
• Riley CM, Sciurba FC. Diagnosis and outpatient management of chronic obstructive pulmonary disease: a review. JAMA. 2019;321(8):786–797. doi: 10.1001/jama.2019.0131
   PubMed Web of Science ®Google Scholar
• World Health Organization. Chronic obstructive pulmonary disease (COPD). [cited Nov 14, 2022]. Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)
   Google Scholar
• Centers for Disease Control and Prevention. Chronic obstructive pulmonary disease (COPD). [cited 2022 Nov 14]. Available from: https://www.cdc.gov/copd/index.html
   Google Scholar
• Centers for Disease Control and Prevention. Chronic obstructive pulmonary disease (COPD). [cited 2022 Nov 14]. Available from: https://www.cdc.gov/copd/infographics/copd-costs.html
   Google Scholar
• Patel JG, Coutinho AD, Lunacsek OE, et al. COPD affects worker productivity and health care costs. Int J Chron Obstruct Pulmon Dis. 2018;13:2301–2311. doi: 10.2147/COPD.S163795
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page C, Rogliani P, et al. Dual bronchodilation for the treatment of COPD: from bench to bedside. Br J Clin Pharmacol. 2022;88(8):3657–3673. doi: 10.1111/bcp.15390
   PubMed Web of Science ®Google Scholar
• Dhar R, Talwar D, Salvi S, et al. Use of single-inhaler triple therapy in the management of obstructive airway disease: Indian medical experts’ review. ERJ Open Res. 2022;8(1):00556–2021. doi: 10.1183/23120541.00556-2021
   PubMedGoogle Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582. doi: 10.1164/rccm.201701-0218PP
   PubMed Web of Science ®Google Scholar
• Bloom CI, Montonen J, Jöns O, et al. First maintenance therapy for chronic obstructive pulmonary disease: retrospective analyses of US and UK healthcare databases. Pulm Ther. 2022;8(1):57–74. doi: 10.1007/s41030-021-00179-0
   PubMedGoogle Scholar
• Bloom CI, Montonen J, Jöns O, et al. Treatment transitions in chronic obstructive pulmonary disease: retrospective analyses of US and UK healthcare databases. Pulm Ther. 2022;8(1):75–93. doi: 10.1007/s41030-021-00180-7
   PubMedGoogle Scholar
• Bhatt SP, Blauer-Peterson C, Buysman EK, et al. Trends and characteristics of Global Initiative for Chronic Obstructive Lung Disease guidelines-discordant prescribing of triple therapy among patients with COPD. Chronic Obstr Pulm Dis. 2022;9(2):135–153. doi: 10.15326/jcopdf.2021.0256
   PubMed Web of Science ®Google Scholar
• Cukic V, Lovre V, Dragisic D, et al. Asthma and chronic obstructive pulmonary disease (COPD)—differences and similarities. Mater Sociomed. 2012;24(2):100–105. doi: 10.5455/msm.2012.24.100-105
   PubMedGoogle Scholar
• Roman-Rodriguez M, Kaplan A. GOLD 2021 strategy report: implications for asthma-COPD overlap. Int J Chron Obstruct Pulmon Dis. 2021;16:1709–1715. doi: 10.2147/COPD.S300902
   PubMed Web of Science ®Google Scholar
• Mekov E, Nuñez A, Sin DD, et al. Update on asthma-COPD overlap (ACO): a narrative review. Int J Chron Obstruct Pulmon Dis. 2021;16:1783–1799. doi: 10.2147/COPD.S312560
   PubMed Web of Science ®Google Scholar
• Griffith MF, Feemster LC, Zeliadt SB, et al. Overuse and misuse of inhaled corticosteroids among veterans with COPD: a cross-sectional study evaluating targets for de-implementation. J Gen Intern Med. 2020;35(3):679–686. doi: 10.1007/s11606-019-05461-1
   PubMed Web of Science ®Google Scholar
• Thomson NC, Polosa R, Sin DD. Cigarette smoking and asthma. J Allergy Clin Immunol Pract. 2022;10(11):2783–2797. doi: 10.1016/j.jaip.2022.04.034
   PubMedGoogle Scholar
• Chen FJ, Huang XY, Liu YL, et al. Importance of fractional exhaled nitric oxide in the differentiation of asthma-COPD overlap syndrome, asthma, and COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:2385–2390. doi: 10.2147/COPD.S115378
   PubMed Web of Science ®Google Scholar
• Yayan J, Rasche K. Asthma and COPD: similarities and differences in the pathophysiology, diagnosis and therapy. Adv Exp Med Biol. 2016;910:31–38.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma [Internet]. Global strategy for asthma management and prevention: updated 2023 2023. [cited 2023 Oct 13]. Available from: https://ginasthma.org/2023-gina-main-report/
   Google Scholar
• Sin DD, Man SFP. Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Eur Respir J. 2003;21(2):260–266. doi: 10.1183/09031936.03.00040803
   PubMed Web of Science ®Google Scholar
• Kaplan AG. Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice. Int J Chron Obstruct Pulmon Dis. 2015;10:2535–2548. doi: 10.2147/COPD.S93321
   PubMed Web of Science ®Google Scholar
• Cataldo D, Derom E, Liistro G, et al. Overuse of inhaled corticosteroids in COPD: five questions for withdrawal in daily practice. Int J Chron Obstruct Pulmon Dis. 2018;13:2089–2099. doi: 10.2147/COPD.S164259
   PubMed Web of Science ®Google Scholar
• George L, Brightling CE. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis. 2016;7(1):34–51. doi: 10.1177/2040622315609251
   PubMed Web of Science ®Google Scholar
• Adcock IM, Bhatt SP, Balkissoon R, et al. The use of inhaled corticosteroids for patients with COPD who continue to smoke cigarettes: an evaluation of current practice. Am J Med. 2022;135(3):302–312. doi: 10.1016/j.amjmed.2021.09.006
   PubMed Web of Science ®Google Scholar
• Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361(9356):449–456. doi: 10.1016/S0140-6736(03)12459-2
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789. doi: 10.1056/NEJMoa063070
   PubMed Web of Science ®Google Scholar
• Suissa S, Ernst P, Vandemheen KL, et al. Methodological issues in therapeutic trials of COPD. Eur Respir J. 2008;31(5):927–933. doi: 10.1183/09031936.00098307
   PubMed Web of Science ®Google Scholar
• Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res. 2009;10(1):59. doi: 10.1186/1465-9921-10-59
   PubMedGoogle Scholar
• Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817–1826. doi: 10.1016/S0140-6736(16)30069-1
   PubMed Web of Science ®Google Scholar
• Soriano JB, Vestbo J, Pride NB, et al. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J. 2002;20(4):819–825. doi: 10.1183/09031936.02.00301302
   PubMed Web of Science ®Google Scholar
• Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet. 1998;351(9105):773–780. doi: 10.1016/S0140-6736(97)03471-5
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Löfdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society study on chronic obstructive pulmonary disease. N Engl J Med. 1999;340(25):1948–1953. doi: 10.1056/NEJM199906243402503
   PubMed Web of Science ®Google Scholar
• Vestbo J, Sørensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999;353(9167):1819–1823. doi: 10.1016/S0140-6736(98)10019-3
   PubMed Web of Science ®Google Scholar
• Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320(7245):1297–1303. doi: 10.1136/bmj.320.7245.1297
   PubMed Web of Science ®Google Scholar
• Lung Health Study Research Group, Wise R, Connett J, et al. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343(26):1902–1909.
   PubMed Web of Science ®Google Scholar
• Christenson SA, Steiling K, van den Berge M, et al. Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;191(7):758–766. doi: 10.1164/rccm.201408-1458OC
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19–26. doi: 10.1164/rccm.200707-973OC
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234. doi: 10.1056/NEJMoa1516385
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Price D, Anzueto A, et al. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:907–922. doi: 10.2147/COPD.S130482
   PubMed Web of Science ®Google Scholar
• Horita N, Goto A, Shibata Y, et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2017;2:CD012066.
   PubMed Web of Science ®Google Scholar
• Skolnik NS, Nguyen TS, Shrestha A, et al. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β2-agonist bronchodilators. Postgrad Med. 2020;132(2):198–205. doi: 10.1080/00325481.2019.1702834
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Boucot I, et al. Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial. Eur Respir J. 2018;52(Suppl 62):A4384.
   Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi: 10.1056/NEJMoa1713901
   PubMed Web of Science ®Google Scholar
• Pascoe S, Barnes N, Brusselle G, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019;7(9):745–756. doi: 10.1016/S2213-2600(19)30190-0
   PubMed Web of Science ®Google Scholar
• Franssen FM, Alter P, Bar N, et al. Personalized medicine for patients with COPD: where are we? Int J Chron Obstruct Pulmon Dis. 2019;14:1465–1484. doi: 10.2147/COPD.S175706
   PubMed Web of Science ®Google Scholar
• Ni S, Fu Z, Zhao J, et al. Inhaled corticosteroids (ICS) and risk of mycobacterium in patients with chronic respiratory diseases: a meta-analysis. J Thorac Dis. 2014;6(7):971–978. doi: 10.3978/j.issn.2072-1439.2014.07.03
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Auladell-Rispau A, Monteagudo M, et al. Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. Eur Respir Rev. 2021;30(160):210075. doi: 10.1183/16000617.0075-2021
   PubMed Web of Science ®Google Scholar
• Festic E, Bansal V, Gupta E, et al. Association of inhaled corticosteroids with incident pneumonia and mortality in COPD patients; systematic review and meta-analysis. COPD: J Chronic Obstructive Pulmonary Dis. 2016;13(3):312–326. doi: 10.3109/15412555.2015.1081162
   PubMed Web of Science ®Google Scholar
• Ashdown HF, Smith M, McFadden E, et al. Blood eosinophils to guide inhaled maintenance therapy in a primary care COPD population. ERJ Open Res. 2021;8(1):00606–2021. doi: 10.1183/23120541.00606-2021
   PubMedGoogle Scholar
• Keir HR, Contoli M, Chalmers JD. Inhaled corticosteroids and the lung microbiome in COPD. Biomedicines. 2021;9(10):1312. doi: 10.3390/biomedicines9101312
   PubMed Web of Science ®Google Scholar
• Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J. 2015;45(2):525–537. doi: 10.1183/09031936.00128914
   PubMed Web of Science ®Google Scholar
• BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD guidelines group of the standards of care committee of the BTS. Thorax. 1997;52(Suppl 5):S1–S28. doi: 10.1136/thx.52.2008.S1.5
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Agusti A, Roche N, et al. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet. 2015;385(9979):1789–1798. doi: 10.1016/S0140-6736(15)60693-6
   PubMed Web of Science ®Google Scholar
• Deas SD, Huprikar N. Dual bronchodilator therapy for chronic obstructive pulmonary disease: evidence for the efficacy and safety of fixed dose combination treatments in the setting of recent guideline updates. Curr Opin Pulm Med. 2018;24(2):130–137. doi: 10.1097/MCP.0000000000000450
   PubMed Web of Science ®Google Scholar
• Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(9):e56–e69. doi: 10.1164/rccm.202003-0625ST
   PubMed Web of Science ®Google Scholar
• Va/dod clinical practice guideline for the management of chronic obstructive pulmonary disease. [cited 2022 Nov 14]. Available from: https://www.healthquality.va.gov/guidelines/cd/copd/
   Google Scholar
• Stevermer JJ, Fisher L, Lin KW, et al. Pharmacologic management of COPD exacerbations: a clinical practice guideline from the AAFP. Am Fam Physician. 2021;104(1). Online. https://www.aafp.org/pubs/afp/issues/2021/0700/od1.html
   PubMedGoogle Scholar
• Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of physicians, American College of chest physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155(3):179–191. doi: 10.7326/0003-4819-155-3-201108020-00008
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management: updated 2019. [cited 2023 Oct 14]. Available from: https://www.nice.org.uk/guidance/ng115/resources/chronic-obstructive-pulmonary-disease-in-over-16s-diagnosis-and-management-pdf-66141600098245
   Google Scholar
• Rinne ST, Wiener RS, Chen Y, et al. Impact of guideline changes on indications for inhaled corticosteroids among veterans with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(9):1226–1228. doi: 10.1164/rccm.201803-0554LE
   PubMed Web of Science ®Google Scholar
• Bahremand T, Etminan M, Roshan-Moniri N, et al. Are COPD prescription patterns aligned with guidelines? Evidence from a Canadian population-based study. Int J Chron Obstruct Pulmon Dis. 2021;16:751–759. doi: 10.2147/COPD.S290805
   PubMed Web of Science ®Google Scholar
• Schabert V, Shah S, Holmgren U, et al. Prescribing pathways to triple therapy in patients with chronic obstructive pulmonary disease in the United States. Ther Adv Respir Dis. 2021;15(17534666211001018):17534666211001018. doi: 10.1177/17534666211001018
   Google Scholar
• Chronic Obstructive Pulmonary Disease (COPD). Market insight, epidemiology and market forecast. Available from. 2032:https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
   Google Scholar
• Raluy-Callado M, Lambrelli D, MacLachlan S, et al. Epidemiology, severity, and treatment of chronic obstructive pulmonary disease in the United Kingdom by GOLD 2013. Int J Chron Obstruct Pulmon Dis. 2015;10:925–937. doi: 10.2147/COPD.S82064
   PubMed Web of Science ®Google Scholar
• Goossens LMA, Leimer I, Metzdorf N, et al. Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial. BMC Pulm Med. 2014;14(1):163. doi: 10.1186/1471-2466-14-163
   PubMedGoogle Scholar
• Moretz C, Hahn B, White J, et al. Symptom burden and GOLD classification in Medicare Advantage patients with COPD initiating umeclidinium/vilanterol or fluticasone propionate/salmeterol therapy. Int J Chron Obstruct Pulmon Dis. 2020;15:2715–2725. doi: 10.2147/COPD.S265037
   PubMed Web of Science ®Google Scholar
• Mannino D, Siddall J, Small M, et al. Treatment patterns for chronic obstructive pulmonary disease (COPD) in the United States: results from an observational cross-sectional physician and patient survey. Int J Chron Obstruct Pulmon Dis. 2022;17:749–761. doi: 10.2147/COPD.S340794
   PubMed Web of Science ®Google Scholar
• Simeone JC, Luthra R, Kaila S, et al. Initiation of triple therapy maintenance treatment among patients with COPD in the US. Int J Chron Obstruct Pulmon Dis. 2017;12:73–83. doi: 10.2147/COPD.S122013
   PubMed Web of Science ®Google Scholar
• Li Y, Lim J, Stemkowski S, et al. Initiation of triple therapy maintenance treatment among patients with COPD. Am J Manag Care. 2020;26(4):e106–e112.
   PubMed Web of Science ®Google Scholar
• Müllerová H, Lu C, Li H, et al. Prevalence and burden of breathlessness in patients with chronic obstructive pulmonary disease managed in primary care. PLoS One. 2014;9(1):e85540. doi: 10.1371/journal.pone.0085540
   PubMed Web of Science ®Google Scholar
• Brusselle G, Price D, Gruffydd-Jones K. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis. 2015;10:2207–2217. doi: 10.2147/COPD.S91694
   PubMed Web of Science ®Google Scholar
• Wurst KE, Punekar YS, Shukla A, et al. Treatment evolution after COPD diagnosis in the UK primary care setting. PLoS One. 2014;9(9):e105296. doi: 10.1371/journal.pone.0105296
   PubMed Web of Science ®Google Scholar
• Bloom CI, Elkin SL, Quint JK. Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016. Int J Chron Obstruct Pulmon Dis. 2019;14:279–287. doi: 10.2147/COPD.S190086
   PubMed Web of Science ®Google Scholar
• Buhl R, Criée CP, Kardos P, et al. Dual bronchodilation vs triple therapy in the “real-life’” COPD DACCORD study. Int J Chron Obstruct Pulmon Dis. 2018;13:2557–2568. doi: 10.2147/COPD.S169958
   PubMed Web of Science ®Google Scholar
• Jarad NA, Wedzicha JA, Burge PS, et al. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir Med. 1999;93(3):161–166. doi: 10.1016/S0954-6111(99)90001-X
   PubMed Web of Science ®Google Scholar
• Donohue JF, Worsley S, Zhu CQ, et al. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med. 2015;109(7):870–881. doi: 10.1016/j.rmed.2015.04.018
   PubMed Web of Science ®Google Scholar
• Singh D, Worsley S, Zhu CQ, et al. Umeclidinium/Vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulm Med. 2015;15(1):91. doi: 10.1186/s12890-015-0092-1
   PubMedGoogle Scholar
• Zhong N, Wang C, Zhou X, et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:1015–1026. doi: 10.2147/COPD.S84436
   PubMed Web of Science ®Google Scholar
• Beeh KM, Derom E, Echave-Sustaeta J, et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study). Int J Chron Obstruct Pulmon Dis. 2016;11:193–205. doi: 10.2147/COPD.S95055
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Paggiaro PL, Dorca J, et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. Eur Respir J. 2016;48(4):1030–1039. doi: 10.1183/13993003.00216-2016
   PubMed Web of Science ®Google Scholar
• Kaplan A, Chapman KR, Anees SM, et al. Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study. Int J Chron Obstruct Pulmon Dis. 2019;14:249–260. doi: 10.2147/COPD.S185485
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Comparative effectiveness and safety of LABA-LAMA vs LABA-ICS treatment of COPD in real-world clinical practice. Chest. 2019;155(6):1158–1165. doi: 10.1016/j.chest.2019.03.005
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1(1):51–60. doi: 10.1016/S2213-2600(12)70052-8
   PubMed Web of Science ®Google Scholar
• Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285–1294. doi: 10.1056/NEJMoa1407154
   PubMed Web of Science ®Google Scholar
• Stolz D, Miravitlles M. The right treatment for the right patient with COPD: lessons from the IMPACT trial. Eur Respir J. 2020;55(5):2000881. doi: 10.1183/13993003.00881-2020
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’aniello S, Ernst P. Triple inhaler versus dual bronchodilator therapy in COPD: real-world effectiveness on mortality. COPD J Chronic Obstruct Pulm Dis. 2022;19(1):1–9. doi: 10.1080/15412555.2021.1977789
   PubMed Web of Science ®Google Scholar
• Buhl R, Mattiucci-Gühlke M, Eckhardt S, et al. EVELUT®: dyspnea and symptom burden in COPD patients switching from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS. In: Eastern pulmonary conferences; Palm Beach, FL: 2022.
   Google Scholar
• Chen H, Sun J, Huang Q, et al. Inhaled corticosteroids and the pneumonia risk in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials. Front Pharmacol. 2021;12:691621. doi: 10.3389/fphar.2021.691621
   PubMed Web of Science ®Google Scholar
• Kardos P, Vogelmeier C, Worth H, et al. A two-year evaluation of the ‘real life’ impact of COPD on patients in Germany: the DACCORD observational study. Respir med. 2017;124:57–64. doi: 10.1016/j.rmed.2017.02.007
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al., Evaluation of COPD Longitudinally to Identify Predictive Surrogate endpoints (ECLIPSE) investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi: 10.1056/NEJMoa0909883
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Worth H, Buhl R, et al. Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD ‘real world’ study. Respir Res. 2022;23(1):109. doi: 10.1186/s12931-022-02037-2
   PubMed Web of Science ®Google Scholar
• Rossi A, Guerriero M, Corrado A. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res. 2014;15(1):77. doi: 10.1186/1465-9921-15-77
   PubMed Web of Science ®Google Scholar
• Rossi A, van der Molen T, del Olmo R, et al. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J. 2014;44(6):1548–1556. doi: 10.1183/09031936.00126814
   PubMed Web of Science ®Google Scholar
• Han MK, Criner GJ, Dransfield MT, et al. The effect of inhaled corticosteroid withdrawal and baseline inhaled treatment on exacerbations in the IMPACT study. A randomized, double-blind, multicenter clinical trial. Am J Respir Crit Care Med. 2020;202(9):1237–1243. doi: 10.1164/rccm.201912-2478OC
   PubMed Web of Science ®Google Scholar
• Suissa S. Perplexing mortality data from triple therapy trials in COPD. Lancet Respir Med. 2021;9(7):684–685. doi: 10.1016/S2213-2600(21)00238-1
   PubMed Web of Science ®Google Scholar
• Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201(12):1508–1516. doi: 10.1164/rccm.201911-2207OC
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Shaikh A, Tetzlaff K, et al. Effect of inhaled corticosteroid withdrawal on chronic obstructive pulmonary disease exacerbations in patients taking triple therapy at baseline. Int J Chron Obstruct Pulmon Dis. 2020;15: 2879–2888. 10.2147/COPD.S237408.
   PubMed Web of Science ®Google Scholar
• Sethi S, Palli SR, Bengtson LGS, et al. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol. J Manag Care Spec Pharm. 2023;29(7):791–806. doi: 10.18553/jmcp.2023.22373
   PubMed Web of Science ®Google Scholar
• Iannella H, Luna C, Waterer G. Inhaled corticosteroids and the increased risk of pneumonia: what’s new? A 2015 updated review. Ther Adv Respir Dis. 2016;10(3):235–255. doi: 10.1177/1753465816630208
   PubMed Web of Science ®Google Scholar
• Souliotis K, Silva Miguel L, Hillas G, et al. The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation: a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2020;14:1753466620926802. doi: 10.1177/1753466620926802
   Web of Science ®Google Scholar
• Quint JK, Montonen J, Esposito DB, et al. Effectiveness and safety of COPD maintenance therapy with tiotropium/olodaterol versus LABA/ICS in a US claims database. Adv Ther. 2021;38(5):2249–2270. doi: 10.1007/s12325-021-01646-5
   PubMed Web of Science ®Google Scholar
• Treharne C, Brighton N, Strange C, et al. 5-year US COPD exacerbation costs extrapolated from rhe ETHOS study. Chest. 2021;160(4):A1838–A1839. doi: 10.1016/j.chest.2021.07.1651
   Web of Science ®Google Scholar
• Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48. doi: 10.1056/NEJMoa1916046
   PubMed Web of Science ®Google Scholar
• Lusuardi M. Respiratory medicine in general practice: what is the role of the pulmonary specialist? Monaldi Arch Chest Dis. 2005;63(1):3–5. doi: 10.4081/monaldi.2005.650
   PubMedGoogle Scholar
• Singh D, Holmes S, Adams C, et al. Overcoming therapeutic inertia to reduce the risk of COPD exacerbations: four action points for healthcare professionals. Int J Chron Obstruct Pulmon Dis. 2021;16:3009–3016. doi: 10.2147/COPD.S329316
   PubMed Web of Science ®Google Scholar
• Oshagbemi OA, Burden AM, Braeken DCW, et al. Stability of blood eosinophils in patients with chronic obstructive pulmonary disease and in control Subjects, and the Impact of Sex, age, smoking, and baseline counts. Am J Respir Crit Care Med. 2017;195(10):1402–1404. doi: 10.1164/rccm.201701-0009LE
   PubMed Web of Science ®Google Scholar